DiscoverEAU PodcastsDr. Constance Thibault talks about triplet therapy in mHSPC
Dr. Constance Thibault talks about triplet therapy in mHSPC

Dr. Constance Thibault talks about triplet therapy in mHSPC

Update: 2022-10-29
Share

Description

In this edition, Dr. Constance Thibault (FR), associate editor of the UROONCO PCa educational platform, discusses triplet therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). 

In the last decade, the outcome of metastatic prostate cancer has been improved by intensifying the systemic therapy with the addition of docetaxel and/or new hormonal therapies. Clinicians now have several treatment options to offer their patients with mHSPC. This raises the issue of the optimal choice? 

Dr. Thibault answers questions about why triplet therapy (ADT + DOCETAXEL + NHT) is recommended to mHSPC patients, and do all patients benefit from a triplet therapy or only specific subgroups?

Lastly, Dr. Thibault talks about which triplet therapy is recommended to use in clinical practice assuming that abiraterone and darolutamide are both approved in combination with ADT + DOCETAXEL for mHSPC patients. 

Comments 
In Channel
loading
Download from Google Play
Download from App Store
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Dr. Constance Thibault talks about triplet therapy in mHSPC

Dr. Constance Thibault talks about triplet therapy in mHSPC

European Association of Urology